Abstract
INTRODUCTION: We aimed to unravel the underlying pathophysiology of the neurodegeneration (N) markers neurogranin (Ng), neurofilament light (NfL), and hippocampal volume (HCV), in Alzheimer's disease (AD) using cerebrospinal fluid (CSF) proteomics. METHODS: Individuals without dementia were classified as A+ (CSF amyloid beta [Aβ]42), T+ (CSF phosphorylated tau181), and N+ or N− based on Ng, NfL, or HCV separately. CSF proteomics were generated and compared between groups using analysis of covariance. RESULTS: Only a few individuals were A+T+Ng−. A+T+Ng+ and A+T+NfL+ showed different proteomic profiles compared to A+T+Ng− and A+T+NfL−, respectively. Both Ng+ and NfL+ were associated with neuroplasticity, though in opposite directions. Compared to A+T+HCV−, A+T+HCV+ showed few proteomic changes, associated with oxidative stress. DISCUSSION: Different N markers are associated with distinct neurodegenerative processes and should not be equated. N markers may differentially complement disease staging beyond amyloid and tau. Our findings suggest that Ng may not be an optimal N marker, given its low incongruency with tau pathophysiology. Highlights: In Alzheimer's disease, neurogranin (Ng)+, neurofilament light (NfL)+, and hippocampal volume (HCV)+ showed differential protein expression in cerebrospinal fluid. Ng+ and NfL+ were associated with neuroplasticity, although in opposite directions. HCV+ showed few proteomic changes, related to oxidative stress. Neurodegeneration (N) markers may differentially refine disease staging beyond amyloid and tau. Ng might not be an optimal N marker, as it relates more closely to tau.
| Original language | English |
|---|---|
| Journal | Alzheimer's and Dementia |
| Volume | 20 |
| Issue number | 9 |
| Pages (from-to) | 6205-6220 |
| Number of pages | 16 |
| ISSN | 1552-5260 |
| DOIs | |
| Publication status | Published - 09.2024 |
Funding
| Funders | Funder number |
|---|---|
| Alzheimer’s Association | |
| Erling‐Persson Family Foundation | |
| Seventh Framework Programme | |
| Foundation for Barnes-Jewish Hospital | |
| National Institute on Aging | K23AG053426, P01AG003991, P30AG066444, P01AG026276 |
| Cure Alzheimer's Fund | |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | |
| Siemens CT | |
| Manchester Biomedical Research Centre | |
| Netherlands Organization for Health Research and Development | 733050502 |
| European Union's Horizon 2020 research and innovation programme | 860197 |
| Schweizerischer Nationalfonds (SNF) | 320030_141179, 320030_204886 |
| EU Joint Programme – Neurodegenerative Disease Research | JPND2021‐00694 |
| EPND | 101034344 |
| AMYPAD | IMI 2 JU, 806999, 115952 |
| UK Dementia Research Institute | UKDRI‐1003 |
| Redefining Alzheimer's disease | 733050824736 |
| Synapsis Foundation – Dementia Research Switzerland | 2017‐PI01 |
| European Union’s Horizon Europe research and innovation programme | 101053962, 71320 |
| EMIF | 115372 |
| Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden | #FO2022‐0270 |
| Stichting Alzheimer Onderzoek | SAO‐FRA 2021/0022 |
| Alzheimer's Drug Discovery Foundation | 201809‐2016862 |
| SNAP VIMP | 7330505021 |
| Swedish Research Council | 2019‐02397, 2023‐00356, 2022‐01018 |
| European Commission within the 5th framework program | 37670, QLRT‐2001‐2455 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Medical Genetics
DFG Research Classification Scheme
- 2.23-06 Molecular and Cellular Neurology and Neuropathology
Fingerprint
Dive into the research topics of 'CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver